Skip to main content
CNSY
NASDAQ Life Sciences

Cerenome Posts First $0.7M Diagnostic Revenue but Cash Drops to $4.9M

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.96
Mkt Cap
$7.212M
52W Low
$0.429
52W High
$18.885
52W Position info
124% above low
Off High info
95% below high
Rel. Volume info
10× avg
Market data snapshot near publication time

CNSY has more than doubled off its 52-week low of $0.429 on elevated volume (10× avg).

Summary

Cerenome booked its first $0.7 million of net diagnostic revenue in Q3 2026 on roughly $1.55 million in gross billings at list prices, but the net loss widened to $8.7 million, or $1.14 per share, from $4.4 million a year earlier. Cash, cash equivalents and investments fell to $4.9 million from $8.6 million at June 30, and the balance sheet shows negative stockholders' equity of about $0.9 million — the going-concern warning stands. The company raised $3.8 million under its Equity Distribution Agreement after quarter end and closed a senior secured facility of up to $20 million with 3i, LP in September, so near-term funding is thin relative to a $7.5 million quarterly operating loss. Commercial progress is real: payer contracts now cover roughly 190 million lives, about 80% of U.S. private payers, with the Aetna national agreement effective November 1, and Medicare reimbursement is targeted for the first half of 2027. On the therapeutics side, the first 10 patients in the ReSPECT-LM multi-dose study showed no dose-limiting toxicities, and Phase 2 ReSPECT-GBM enrollment finished in October with topline data expected mid-2027. The November 16, 8:30 a.m. ET call will be the first chance for management to address the cash runway.

At the time of this announcement, CNSY was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.43 to $18.89. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CNSY - Latest Insights

CNSY
Nov 13, 2026, 5:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.970
Real-time Price: $0.914 info
Change: -$0.056 (-6%) info
Market Cap: $7.212M info
CNSY
Nov 13, 2026, 4:51 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9372
Real-time Price: $0.914 info
Change: -$0.0232 (-2%) info
Market Cap: $7.212M info
CNSY
Nov 04, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.31
Real-time Price: $0.914 info
Change: -$0.396 (-30%) info
Market Cap: $7.212M info
CNSY
Oct 08, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.914 info
Change: -$0.716 (-44%) info
Market Cap: $7.212M info
CNSY
Sep 30, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $0.914 info
Change: -$1.09 (-54%) info
Market Cap: $7.212M info